BioCryst Pharma (BCRX) Tops Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.68 -0.23%
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $4.3 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
- Can global equities keep rising? UBS sees these factors driving upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
